Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer. (October 2012)

• Record Type: Journal Article
• Authors: Zielinski, Robert; Chi, Kim N
• Is Part Of: Future oncology. Volume 8:Number 10(2012)
• Page Start: 1239
• Page End: 1251
• Publication Date: 2012-10
• Subjects: antisense oligonucleotide -- cancer -- chaperone protein -- clusterin -- custirsen -- prostate cancer; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.12.129
• Languages: English
• ISSNs: 1479-6694

Abstract

Clusterin is a stress-induced cytoprotective chaperone that confers broad-spectrum treatment resistance and is overexpressed across a number of cancers. custirsen (OGX-011) is a promising novel second-generation antisense inhibitor of clusterin in clinical development. This article describes the mechanism of action and safety profile of OGX-011 and details the Phase I and II results in human solid organ malignancies. Two Phase III registration trials are currently under recruitment evaluating OGX-011 in combination with chemotherapy in patients with metastatic castration-resistant prostate cancer. These studies not only have the potential to significantly alter the standard of care in prostate cancer, but would also endorse a new class of targets and targeted therapy approach for cancer.